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the relationship between the NSCLC neuroendocrine markers and
post-operative survival.
Findings: The subtypes of NSCLCs included in the study were
54% squamous-cell carcinomas (SCCs), 32.5% adenocarcinomas,
and 11.5% large-cell lung carcinomas (LCLCs). 10.2%, 17.3%,
15.1%, and 7.4% of NSCLC tissue demonstrated focal to almost dif-
fuse strong cytoplasmic staining of the tumour cells with CgA,
SYN, HDC, and NSE, respectively. Assessing individual subtypes
showed that 3.8%, 5.1%, 6.5%, and 1.8% SCCs, 13.3%, 17.3%, 20%,
and 9% adenocarcinomas, and 21.3%, 28%, 33%, and 16.6% LCLCs
demonstrated positive staining with CgA, SYN, HDC, and NSE,
respectively. HDC expression was stronger and more sensitive
than CgA, SYN, and NSE (p = 0.0063). Multivariate analysis showed
that the NSCLC patients with neuroendocrine markers had signif-
icantly shorter survival (p = 0.031). The following factors were
related to survival: lung-cancer histological differentiation
(p = 0.0057), clinical stage (p = 0.001), and neuroendocrine markers
reaction (p = 0.072).
Interpretation: Neuroendocrine markers in NSCLC are signifi-
cantly associated with cancer-cell differentiation and post-opera-
tive survival. These markers should be applied clinically as
prognostic factors for post-operative survival of NSCLC patients.
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Background: BCL-2 oncoprotein has an important role in cell
development, maturation, and replication by reducing the
requirement for growth factors, and acts as an anti-apoptotic fac-
tor in various neoplastic processes. This study investigated
immunohistochemical expression of BCL-2 protein in uterine
leiomyomas, smooth-muscle tumours of uncertain malignant
potential (STUMP), and leiomyosarcomas (LMS), in female
patients of child-bearing age. The correlation between BCL-2
expression and various clinicopathological parameters was
assessed to evaluate its prognostic value.
Methods: A total of 66 female patients (mean age 37 years, SD
4.5) presenting with uterine leiomyomas (n = 42), STUMP (n = 18),
and LMS (n = 6) from July, 2005, to July, 2006, at the departments
of Gynecology and Obstetrics in tertiary-care hospitals in Lahore,
Pakistan, were included. Paraffin-embedded tissues of these
patients were subjected to BCL-2 immunohistochemistry. Find-
ings were compared and correlated with different clinicopatho-
logical parameters. Clinical information, including follow-up
data until July, 2010, was obtained from the database of the
hospitals.
Findings: Positive BCL-2 immunostaining was observed in two
of six patients with LMS, 11 of 18 with STUMP, and 39 of 42 with
leiomyomas. Frequency of BCL-2 expression and staining inten-
sity were significantly different between LMS and leiomyoma
(p < 0.05), as well as STUMP and leiomyoma (p < 0.05), but not
between LMS and STUMP (p > 0.05). No significant association
was found between BCL-2 immunostaining and tumour size,
age, menstrual history, parity, infertility, contraceptive measures,
or family history of neoplasms. Patients with uterine LMS who
had BCL-2 positive tumours showed less vascular-space involve-
ment and longer overall survival than patients with BCL-2 nega-
tive tumours (p < 0.05).
Interpretation: Expression of BCL-2 oncoprotein is more fre-
quent and strong in leiomyomas than in LMS and STUMP. Stron-
ger BCL-2 expression in benign leiomyomas and the better
clinical outcome of BCL-2-positive LMS indicate that this protein
is a good prognostic factor. Larger studies are needed to establish
BCL-2 as a routine marker for improved prognosis in malignant
uterine smooth-muscle tumours.
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P33 PREDICTION OF PATHOLOGICAL GRADE OF ASTROCYTO-
MAS USING MRI – A NEW METHOD VERSUS CLINICIAN
PERFORMANCE
Z. Zhao, M. He*, C. Wu, K. Lan, J. Xiao, Y. Zhang, L. Jia. West China
Hospital and West China School of Medicine, Sichuan University,
Chengdu Sichuan, China
Background: Astrocytoma is the most common glioma and has
poor prognosis, affected by treatment strategy and pathological
grading. Pre-operative assessment of grades is difficult. The aim
of this study was to evaluate a support vector machine (SVM)
model to help clinicians predict grading of astrocytomas.
Methods: 106 patients were recruited at our hospital between
January, 2008, and April, 2009. Two clinicians read MRIs and
scored the appearance of astrocytomas, and a support vector
machine (SVM) model was constructed. From clinicians predic-
tions, predictions of the SVM model, and predictions of clinicians
with the SVMmodel, three receiver operating characteristic (ROC)
curves were created to discriminate low-grade and high-grade
groups.
Findings: The area under the curve (AUC) for clinicians predic-
tions was 0.7881, which was significantly less than the AUC for
the SVM model (0.9370, v2 8.62, p = 0.0033) and the AUC for clini-
cians with the SVM model (0.8829, v2 13.46, p = 0.0002). However,
the AUCs of the SVM model and clinicians with the SVM model
did not differ significantly (v2 1.63, p = 0.2011).
Interpretation: The SVM model is a useful mathematical
method that can help clinicians improve the accuracy of predict-
ing pathological grade of astrocytomas.
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